Regeneron Pharmaceuticals (REGN) Stock Price, Quote & News

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to...

Industry: Biotechnology

Sector: Healthcare

Phone: 914 847 7000

Website: www.regeneron.com

Address:

777 Old Saw Mill River Road, Tarrytown, United States

Whiskeyunderthebed Feb. 3 at 8:29 PM

$REGN one of the few green soldiers in BIO land and the market.

0 · Reply

Sunny3999 Feb. 3 at 4:38 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger. News with $175 Million financing last week! $JNJ $LLY $PFE $PMN $REGN

0 · Reply

Iwannagofast1 Feb. 3 at 3:10 PM

$REGN Boom !!!!

0 · Reply

erevnon Feb. 2 at 6:12 PM

Morgan Stanley maintains Regeneron Pharmaceuticals $REGN at Equal-Weight and raises the price target from $768 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Whiskeyunderthebed Feb. 2 at 5:53 PM

$REGN 5 upgrades out this morning with all new price targets.

0 · Reply

Iwannagofast1 Feb. 2 at 4:17 PM

$REGN Yep yep yep , that’s right you precious stock do your thing.

0 · Reply

erevnon Feb. 2 at 3:45 PM

Cantor Fitzgerald maintains Regeneron Pharmaceuticals $REGN at Overweight and raises the price target from $740 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsNews Feb. 2 at 9:09 AM

Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock? $REGN https://stocktwits.com/news/equity/markets/regeneron-stock-slips-premarket-even-after-wall-street-lifts-targets-on-strong-q4/cZbg0a7R4jx

0 · Reply

PickAlpha Jan. 31 at 1:28 PM

3/3: Regeneron beats Q4 profit estimates on Dupixent strength; Eylea revenues fall 28% amid biosimilar pressure | View: Earnings beat and Dupixent momentum are offset by accelerating Eylea pressure and pending U.S.… $REGN $SNY $XLV

0 · Reply

therealpoub Jan. 31 at 5:37 AM

$XERS hey $REGN I like the 3rd paragraph: "With $19B on the balance sheet and a view that their internal pipeline, while broad, could benefit from additional potentially-transformative revenue drivers, we believe larger-scale external BD would be well received, if that is indeed what the company is hinting at," he said. https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/

1 · Reply

These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Feb 2, 2026, 7:00 AM EST - 1 day ago

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

Jan 31, 2026, 8:33 AM EST - 3 days ago

Regeneron: Expect Double-Digit Growth In 2026

Jan 30, 2026, 3:10 PM EST - 4 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript

Jan 30, 2026, 12:42 PM EST - 4 days ago

Regeneron bets added cholesterol benefit will help its obesity drug stand out

Jan 30, 2026, 10:56 AM EST - 4 days ago

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Jan 30, 2026, 7:37 AM EST - 4 days ago

Regeneron beats quarterly profit estimates on Dupixent strength

Jan 30, 2026, 6:30 AM EST - 4 days ago

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Jan 30, 2026, 4:10 AM EST - 4 days ago

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Jan 23, 2026, 3:25 PM EST - 11 days ago

Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026

Jan 21, 2026, 12:05 PM EST - 13 days ago

Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Jan 12, 2026, 8:16 PM EST - 22 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 1:30 PM EST - 22 days ago

Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba

BABA COF UNH

Jan 7, 2026, 4:18 PM EST - 27 days ago

Regeneron Just Moved From Underperform To Buy - Here's Why

Dec 23, 2025, 1:00 AM EST - 6 weeks ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

SNY

Dec 23, 2025, 1:00 AM EST - 6 weeks ago

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Dec 22, 2025, 4:05 PM EST - 6 weeks ago

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Dec 20, 2025, 9:30 AM EST - 6 weeks ago

Regeneron: The Turnaround Is Gaining Steam

Dec 10, 2025, 1:31 PM EST - 7 weeks ago

Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv

BKNG FISV GD

Dec 10, 2025, 12:42 PM EST - 7 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

Dec 10, 2025, 12:20 PM EST - 7 weeks ago

Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial

Dec 8, 2025, 2:46 PM EST - 2 months ago

Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?

Dec 7, 2025, 4:30 PM EST - 2 months ago

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Dec 6, 2025, 9:33 AM EST - 2 months ago

Regeneron's experimental therapy combo effective in untreated cancer patients

Dec 3, 2025, 2:13 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 4:53 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 7:00 AM EST - 2 months ago

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Nov 25, 2025, 1:00 AM EST - 2 months ago

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Nov 25, 2025, 1:00 AM EST - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

SNY

Nov 21, 2025, 11:05 AM EST - 2 months ago

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

LLY

Nov 20, 2025, 11:52 AM EST - 2 months ago

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

Nov 19, 2025, 4:10 PM EST - 2 months ago

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Nov 19, 2025, 7:00 AM EST - 2 months ago

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Nov 17, 2025, 1:07 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 17, 2025, 11:57 AM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 13, 2025, 7:00 AM EST - 2 months ago

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Nov 12, 2025, 6:20 PM EST - 2 months ago

Final Trade: LMAT, REGN, BA, TJX

TJX BA LMAT

Nov 10, 2025, 2:31 PM EST - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript

Nov 7, 2025, 8:00 AM EST - 3 months ago

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

SNY

Nov 3, 2025, 4:05 PM EST - 3 months ago

Regeneron Announces Investor Conference Presentations

Oct 31, 2025, 7:00 AM EDT - 3 months ago

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Oct 29, 2025, 1:00 PM EDT - 3 months ago

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Oct 29, 2025, 12:01 PM EDT - 3 months ago

Market Starting To Embrace The 'New' Regeneron

Oct 28, 2025, 1:31 PM EDT - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 9:13 AM EDT - 3 months ago

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Oct 28, 2025, 7:30 AM EDT - 3 months ago

Regeneron beats quarterly estimates on strong demand for Dupixent

Oct 28, 2025, 6:30 AM EDT - 3 months ago

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Oct 27, 2025, 8:35 AM EDT - 3 months ago

Has Regeneron Stock Quietly Become A Value Buy?

Oct 24, 2025, 4:30 AM EDT - 3 months ago

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FISV IQV IVZ JNJ

Oct 23, 2025, 7:30 PM EDT - 3 months ago

7 Stocks Taking The Next Step To Be On Offense

ACI BIO CNX FCF FDX FIS IAC

Whiskeyunderthebed Feb. 3 at 8:29 PM

$REGN one of the few green soldiers in BIO land and the market.

0 · Reply

Sunny3999 Feb. 3 at 4:38 PM

0 · Reply

Iwannagofast1 Feb. 3 at 3:10 PM

$REGN Boom !!!!

0 · Reply

erevnon Feb. 2 at 6:12 PM

Morgan Stanley maintains Regeneron Pharmaceuticals $REGN at Equal-Weight and raises the price target from $768 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Whiskeyunderthebed Feb. 2 at 5:53 PM

$REGN 5 upgrades out this morning with all new price targets.

0 · Reply

Iwannagofast1 Feb. 2 at 4:17 PM

$REGN Yep yep yep , that’s right you precious stock do your thing.

0 · Reply

erevnon Feb. 2 at 3:45 PM

Cantor Fitzgerald maintains Regeneron Pharmaceuticals $REGN at Overweight and raises the price target from $740 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsNews Feb. 2 at 9:09 AM

0 · Reply

PickAlpha Jan. 31 at 1:28 PM

0 · Reply

therealpoub Jan. 31 at 5:37 AM

1 · Reply

3DBuilds Jan. 31 at 5:13 AM

$BEAM $BMY $JNJ $NTLA $REGN

0 · Reply

ZacksResearch Jan. 30 at 6:35 PM

$REGN Q4 earnings beat expectations — but shares slip. Why? 🤔 🩺 EPS of $11.44 beat the $10.56 estimate, but down 5% YoY. 💊 Eylea HD sales in the US soared 66%, yet total Eylea sales dropped due to competition. 📈 Sanofi's collaboration revenues increased 35% driven by Dupixent profits. Discover the full story here 👉 https://www.zacks.com/stock/news/2826278/regn-q4-earnings-beat-estimates-sales-rise-on-eylea-hd-growth?cid=sm-stocktwits-2-2826278-body-31308&ADID=SYND_STOCKTWITS_TWEET_2_2826278_BODY_31308

0 · Reply

stannoxane Jan. 30 at 5:53 PM

$REGN as if the earning did not even happen….. all those who bought 330 straddles expiring today for 725(put)/775(call)

0 · Reply

ZacksResearch Jan. 30 at 5:35 PM

$REGN beats Q4 earnings — but there’s an important wrinkle here. 👀 Q4 EPS topped estimates as Eylea HD and Dupixent profits lifted revenues, even though higher expenses drove a year-over-year EPS decline. See the full breakdown and what investors should focus on 👉 https://www.zacks.com/stock/news/2826278/regn-q4-earnings-beat-estimates-sales-rise-on-eylea-hd-growth?cid=sm-stocktwits-2-2826278-teaser-31307&ADID=SYND_STOCKTWITS_TWEET_2_2826278_TEASER_31307

0 · Reply

Iwannagofast1 Jan. 30 at 2:27 PM

$REGN No fear riding to 900

0 · Reply

Whiskeyunderthebed Jan. 30 at 2:10 PM

$REGN

0 · Reply

Whiskeyunderthebed Jan. 30 at 2:05 PM

$REGN Briefly turning to. Our new treatment for relapsed refractory multiple myeloma. We are encouraged by the launch progress to date with physicians appreciating its differentiated clinical profile. Less burdensome hospitalization requirements, and convenient dosing regimen. We expect adoption to continue to steadily build over time in this late line setting, with the larger commercial opportunities in earlier lines of therapy. In summary, in the fourth quarter, we delivered strong growth across. ADHD.

0 · Reply

Sunny3999 Jan. 30 at 1:55 PM

$PMN before news of $175 million I wrote this will be a 10bagger $AMGN $GILD $LLY $REGN

0 · Reply

Whiskeyunderthebed Jan. 30 at 1:55 PM

$REGN

0 · Reply

OpenOutcrier Jan. 30 at 1:50 PM

$REGN (-1.7% pre) Regeneron Pharmaceuticals beats top-line and bottom-line estimates; initiates FY26 outlook https://ooc.bz/l/91430

0 · Reply

Whiskeyunderthebed Jan. 30 at 1:50 PM

$REGN FDA submission seeking approval of the Eylea HD prefilled syringe. Using a new manufacturer has been accepted for review. A standard pre-licensing inspection has been scheduled and the decision on our filing is expected in late April. In addition, as a backup Catalan Indiana continues to work with the FDA to resolve findings from a previous inspection. We continue to believe that all three of these product enhancements are key to fully unlocking Eylea's HD commercial potential.

0 · Reply

Whiskeyunderthebed Jan. 30 at 1:48 PM

$REGN

0 · Reply

Market Cap	77.93B
Revenue (ttm)	14.20B
Net Income (ttm)	4.41B
EPS (ttm)	N/A
PE Ratio	20.43
Forward PE	21.51
Profit Margin	31.07%
Debt to Equity Ratio	0.06

Volume	768,600
Avg Vol	940,400
Day's Range	N/A - N/A
Shares Out	105.10M
Stochastic %K	62%
Beta	0.39
Analysts	Strong Sell
Price Target	$835.42